In this episode, CEO and founder Thomas Verstraeten speaks with Edward Sobe-Yarig, our West Africa Operations Lead about what it truly takes to run vaccine trials in Africa today. Drawing on over 20 years of experience, Sobe shares how the continent has moved beyond infrastructure challenges to build advanced capabilities in clinical research.
From trained local professionals and evolving regulations to regional networks and community engagement, this episode offers practical insight for sponsors, CROs, and global health stakeholders considering running vaccine trials in Africa.
https://youtu.be/86EHro6gLY8?si=HY8u2bIcD4bPHyW2
Listen and Subscribe:
From trial site to global scientific leader
In the early 2000s, clinical trials in Africa were often managed externally, with little local control or infrastructure. Sobe recalls using fax machines to send paper CRFs abroad and struggling with reliable internet or logistics.
Today, those barriers have largely been overcome. African researchers trained through international collaborations now lead their own studies. Many institutions are diversifying into areas like sickle cell and oncology. Infrastructure and expertise are in place, and they’re being led from within.
Running vaccine trials in Africa requires smart regulatory navigation
One of the most important developments in recent years has been AVAREF (the African Vaccine Regulatory Forum), a joint review mechanism that coordinates approvals across multiple African countries.
Instead of submitting country by country, sponsors can activate AVAREF to trigger a single ethics and regulatory review; a binding decision accepted across participating nations. Sobe emphasizes the importance of working with local experts and CROs like P95 to navigate this system efficiently and transparently.
Infrastructure and operational readiness are no longer barriers
Sponsors once had to provide basic infrastructure — from internet access to lab equipment — before a trial could even begin. Now, many African sites already have everything needed: modern labs, trained teams, GCP-compliant systems, and quality data capabilities.
However, without ongoing trials, these investments can’t be sustained. Continuity is key. Long-term partners like P95 help keep sites active between studies and ensure readiness is maintained.
“Now you go to sites, they have state-of-the-art laboratories, they have archives, computers. Everything is already there – Sobe” – Sobe
Community engagement is central to trial success
Sobe shares how effective community engagement is now considered a requirement for running trials in Africa. Ethics committees want to see evidence that local leaders and populations have been properly informed and consulted.
Working with chiefs, community health leaders, and using accessible channels like radio has helped increase public trust and improve recruitment. Sponsors running vaccine trials in Africa must build this into planning from the outset.
Genetic diversity and population trends shape trial relevance
Africa’s genetic diversity makes it essential for evaluating global safety and efficacy. Treatments developed elsewhere don’t always translate across populations. Including African participants in vaccine trials strengthens global data.
With Africa projected to account for 40% of all births by 2050, pediatric trials in the region will only become more important. Running trials in Africa isn’t just strategic, it’s necessary for truly global impact.
Running Vaccine trials in Africa: Episode takeaways
“There’s no limit. Africa has come of age.” – Sobe
This episode highlights why running vaccine trials in Africa today is not just feasible, it’s efficient, data-rich, and future-facing. From streamlined approvals to established infrastructure and capable local teams, the environment is ready.
Whether you are considering a first trial in the region or scaling up existing programs, this episode provides the context and confidence you need.
FAQ
Here are some answers to Frequently Asked Questions.
What is the main takeaway from this episode?
Africa is no longer just a location for vaccine trials. It is leading them. With experienced professionals, improved infrastructure, and regional regulatory collaboration, the continent is ready to drive global research forward.
What should sponsors know about running vaccine trials in Africa?
Beyond logistics, it’s about local trust and partnership. Community engagement, site sustainability, and a deep understanding of evolving regulatory processes are key to trial success in the region.
What makes P95 different as a CRO partner in Africa?
P95 combines long-standing partnerships across African sites with deep operational knowledge and local leadership. We don’t just manage trials. We collaborate with and invest in local ecosystems.
Where can I learn more about running vaccine trials in Africa with P95?
Visit our dedicated page about clinical trials in Africa and other LMICs or contact us to arrange a meeting with one of our experts.
Listen or watch now: Episode 2: Africa’s Role in Vaccine Development: More Than a Trial Site
🔗 https://p-95.com/category/podcast/
Got questions or planning trials in Africa? Contact us
0 Comments